Asp-4058

Asp-4058

SCHEMBL3218310

C[C@H](Oc1ccc(-c2nc(-c3ccc4[nH]cnc4c3)no2)cc1C(F)(F)F)C(F)(F)F

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 18/20 0.86
PSMD11 O00231 1/20 0.46
DYRK3 O43781 1/20 0.44
MAP4K4 O95819 1/20 0.44
ERBB2 P04626 1/20 0.44
PIM1 P11309 1/20 0.44
MARK3 P27448 1/20 0.44
PLK1 P53350 1/20 0.44
CAMK2B Q13554 1/20 0.44
CDC42BPA Q5VT25 1/20 0.44
PIM3 Q86V86 1/20 0.44
MINK1 Q8N4C8 1/20 0.44
SRPK1 Q96SB4 1/20 0.44
MKNK2 Q9HBH9 1/20 0.44
MAP3K20 Q9NYL2 1/20 0.44
MAP4K5 Q9Y4K4 1/20 0.44
S1PR3 Q99500 3/20 0.43
S1PR5 Q9H228 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Asp-4058 SCHEMBL29646278 1.00 S1PR1 (0.86) S1PR1PSMD11DYRK3MAP4K4ERBB2
Asp-4058 SCHEMBL1798268 1.00 S1PR1 (0.86) S1PR1PSMD11DYRK3MAP4K4ERBB2
Asp-4058 SCHEMBL3195457 1.00 S1PR1 (0.86) S1PR1PSMD11DYRK3MAP4K4ERBB2
Asp-4058 SCHEMBL3219834 0.99 S1PR1 (0.84) S1PR1PSMD11DYRK3MAP4K4ERBB2
Asp-4058 SCHEMBL22729322 0.99 S1PR1 (0.84) S1PR1PSMD11DYRK3MAP4K4ERBB2
Asp-4058 SCHEMBL3216963 0.99 S1PR1 (0.84) S1PR1PSMD11DYRK3MAP4K4ERBB2
SCHEMBL12619225 0.93 S1PR1 (0.75) S1PR1PSMD11DYRK3MAP4K4ERBB2
SCHEMBL12619235 0.90 S1PR1 (0.70) S1PR1PSMD11S1PR3S1PR5
SCHEMBL12619155 0.89 S1PR1 (0.68) S1PR1PSMD11MAP4K4MINK1S1PR3
SCHEMBL3207522 0.89 S1PR1 (0.68) S1PR1PSMD11MAP4K4MINK1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210113529-A1 MEDICINE FOR PREVENTING OR TREATING OPHTHALMIC DISEASE ASSOCIATED WITH ENHANCED INTRAOCULAR NEOVASCULARIZATION AND/OR INTRAOCULAR VASCULAR PERMEABILITY KYOTO UNIVERSITY (JP) 2021-04-22 US claimed
EP-3747471-A1 MEDICINE FOR PREVENTING OR TREATING OPHTHALMIC DISEASE ASSOCIATED WITH ENHANCED INTRAOCULAR NEOVASCULARIZATION AND/OR INTRAOCULAR VASCULAR PERMEABILITY Kyoto University (JP) 2020-12-09 EP claimed
EP-2990055-B1 COMPOSITION COMPRISING A SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 AGONIST FOR INHIBITING FORMATION AND/OR ENLARGEMENT OF CEREBRAL ANEURYSM OR FOR SHRINKING IT UNIV KYOTO (JP) 2019-06-05 EP claimed
US-9629834-B2 Medicinal composition for inhibiting formation and/or enlargement of cerebral aneurysm or shrinking same KYOTO UNIVERSITY (JP) 2017-04-25 US claimed
US-20160113917-A1 MEDICINAL COMPOSITION FOR INHIBITING FORMATION AND/OR ENLARGEMENT OF CEREBRAL ANEURYSM OR SHRINKING SAME KYOTO UNIVERSITY (JP) 2016-04-28 US claimed
EP-2990055-A1 MEDICINAL COMPOSITION FOR INHIBITING FORMATION AND/OR ENLARGEMENT OF CEREBRAL ANEURYSM OR SHRINKING SAME Kyoto University (JP) 2016-03-02 EP claimed
EP-2003132-B1 Oxadiazole derivatives as S1P1 agonists ASTELLAS PHARMA INC (JP) 2014-03-05 EP claimed
US-7678820-B2 Hetero compound ASTELLAS PHARMA INC. (JP) 2010-03-16 US claimed
US-20090076070-A1 HETERO COMPOUND ASTELLAS PHARMA INC. (JP) 2009-03-19 US claimed
WO-2025083549-A1 METHODS AND COMBINATIONS OF INHIBITORS OF IL-23 PATHWAY AND MODULATORS OF S1P SIGNALING PATHWAY FOR THE TREATMENT OF AUTOIMMUNE DISORDERS SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2025-04-24 WO disclosed
EP-3723801-B9 TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR BIORA THERAPEUTICS INC (US) 2023-10-04 EP disclosed
EP-3723801-B9 TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR BIORA THERAPEUTICS INC (US) 2023-10-04 EP disclosed
EP-3723801-B1 TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR BIORA THERAPEUTICS INC (US) 2023-06-07 EP disclosed
EP-3723801-B1 TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR BIORA THERAPEUTICS INC (US) 2023-06-07 EP disclosed
US-20100168159-A1 HETERO COMPOUND ASTELLAS PHARMA INC. (JP) 2010-07-01 US disclosed
US-20100168159-A1 HETERO COMPOUND ASTELLAS PHARMA INC. (JP) 2010-07-01 US disclosed
US-7678820-B2 Hetero compound ASTELLAS PHARMA INC. (JP) 2010-03-16 US disclosed
US-7678820-B2 Hetero compound ASTELLAS PHARMA INC. (JP) 2010-03-16 US disclosed
US-20090076070-A1 HETERO COMPOUND ASTELLAS PHARMA INC. (JP) 2009-03-19 US disclosed
US-20090076070-A1 HETERO COMPOUND ASTELLAS PHARMA INC. (JP) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168159-A1 HETERO COMPOUND S1PR1, ENPP2, LPAR1 S1PR1 1/4885PSMD11 2632/4885DYRK3 2911/4885
US-20090076070-A1 HETERO COMPOUND S1PR1, ENPP2, LPAR1 S1PR1 1/4885PSMD11 2632/4885DYRK3 2911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.